| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Maze Therapeutics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $503.77M | Series D | 12/3/2024 | $76.4M | $552.39M | $1.38 | Frazier Life Sciences, Deep Track Capital, Janus Henderson Investors, Logos Capital | ||||
 | OM1 | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $176.2M | Series D | 7/16/2021 | $85M | $836.02M | $8.90 | D1 Capital Partners, Kaiser Permanente, Breyer Capital, General Catalyst, Polaris Partners, Scale Venture Partners, 7wire Ventures, Glikvest | ||||
 | R-Zero | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $173.45M | Series C | 2/16/2023 | $105M | $526.86M | $14.13 | BMO Financial Group, Qualcomm Ventures, Upfront Ventures, DBL Partners, World Innovation Lab, Mayo Clinic, Bedrock Capital, SOSV, John Doerr | ||||
 | Shoreline Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $186M | Series B | 11/2/2021 | $140M | $527.99M | $10.07 | Ally Bridge Group, Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, Superstring, BVF Partners, Commodore Capital, Cormorant Asset Management, Janus Henderson Investors, Kite, Stork Capital, Wedbush Healthcare Partners | ||||
 | 98point6 | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $267.22M | Series E | 10/15/2020 | $134.21M | $548.43M | $6.59 | L Catterton, Activant Capital, Goldman Sachs | ||||
 | Acelyrin | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $558M | Series C | 9/9/2022 | $300M | $809.52M | $6.22 | Access Biotechnology, Matrix Capital Management, Westlake Village BioPartners, Cowen Healthcare Investments, Decheng Capital, Marshall Wace, OrbiMed, Samsara BioCapital, Surveyor Capital, Tybourne Capital Management, venBio Partners | ||||
 | Apprentice | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $189.97M | Series C | 3/20/2023 | $151.97M | $622.45M | $12.48 | Alkeon Capital Management, Silverton Partners, Insight Partners, Pacific Western Bank, Colorcon Ventures, ICONIQ Growth | ||||
 | Graviton BioScience | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $208.32M | Series B-1B | 2/26/2025 | $115M | $755.23M | $14.37 | Undisclosed Investors | ||||
 | MapLight Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $511M | Series D | 9/30/2025 | $200M | $883.21M | $0.95 | Catalyst4, Forbion, Sanofi, Novo Holdings | ||||
 | Medrobotics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $197.87M | Series H | 1/26/2017 | $24.2M | $585.16M | $4.84 | Undisclosed Investors | ||||
 | Ollin | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $431.81M | Series B | 6/24/2026 | $331.81M | $876.79M | $3.00 | TCGX, ARCH Venture Partners, Andreessen Horowitz, Blackstone, Commodore Capital, CPP Investments, RA Capital Management, Mubadala Capital, Monograph Capital, T. Rowe Price | ||||
 | Paradigm Health | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $281M | Series B-1 | 12/4/2025 | $57.73M | $505.1M | $1.00 | ARCH Venture Partners, DFJ Growth, F-Prime Capital, General Catalyst, GV, Lux Capital, Mubadala Capital, BrightEdge | ||||
 | Tendo Systems | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $83.48M | Series B | 10/10/2023 | $64.35M | $564.35M | $2.91 | Lux Capital, General Catalyst | ||||
 | Upstream Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $800M | Series B | 6/8/2023 | $200M | $676.16M | $17.00 | Enavate Sciences, Venrock Healthcare Capital Partners, Bain Capital Life Sciences, Wellington Management, OrbiMed, Access Biotechnology, Decheng Capital, Altshuler Shaham Provident Funds Ltd., TCG X, HBM Healthcare Investments, Omega Funds, Samsara BioCapital | ||||
 | Fractyl | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $572.96M | Series F | 6/16/2021 | $100M | $872.9M | $8.38 | Maverick Capital, M28 Capital, Population Health Partners | ||||
 | InterVenn | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $245.77M | Series C | 8/2/2021 | $201.27M | $685.15M | $8.83 | A.G. Hill Partners, Amplify Partners, Anzu Partners, Genoa Ventures, Heritage Provider Network, Highside Capital Management, Irving Investors, Softbank Group, True Ventures | ||||
 | Notable | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $126.5M | Series B | 11/3/2021 | $100M | $600.67M | $3.49 | ICONIQ Growth, Greylock Partners, F-Prime Capital, Oak HC/FT | ||||
 | PROCEPT BioRobotics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $341.8M | Series G | 6/30/2021 | $85M | $872.62M | $4.02 | Fidelity, T. Rowe Price Associates, CPMG, Perceptive Advisors, Viking Global Investors LP, Duquesne Family Office | ||||
 | Profluent | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $150M | Series B | 11/19/2025 | $106M | $502.78M | $34.07 | Altimeter Capital, Bezos Expeditions, Spark Capital, Insight Partners, Air Street Capital | ||||
 | BrightInsight | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $179M | Series C+ | 1/20/2026 | $57.29M | $750.6M | $9.13 | General Catalyst, Insight Partners, New Leaf Venture Partners, Eclipse Ventures, Mayo Clinic | ||||
 | ReCode Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $397.77M | Series B | 9/23/2025 | $290M | $588.16M | $9.23 | Matrix Capital Management, Pfizer Ventures, EcoR1 Capital, Sanofi Ventures, Tekla Capital Management, Superstring Capital, NS Investment, OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, Osage University Partners, Bayer, Amgen, CF Foundation | ||||
 | Sionna Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $331.32M | Series C | 3/6/2024 | $181.86M | $523.7M | $9.76 | Enavate Sciences, Viking Global Investors, Perceptive Advisors, RA Capital, TPG, Atlas Venture, Cystic Fibrosis Foundation, T. Rowe Price, Qatar Investment Authority, OrbiMed | ||||
 | Vividion Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $267.82M | Series C | 2/24/2021 | $135M | $600.09M | $2.10 | Logos Capital, Boxer Capital, SoftBank, Avoro Capital Advisors, BlackRock, RA Capital Management, T. Rowe Price Associates, Surveyor Capital, Woodline Partners, Acuta Capital, Driehaus Capital Management, ARCH Venture Partners, BVF Partners, Casdin Capital, Mubadala Capital, Nextech Invest, Versant Ventures | ||||
 | Expedition Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $280M | Series B | 8/5/2026 | $115M | $599.82M | $7.43 | General Atlantic, RA Capital, Vivo Capital, Novo Holdings, Sofinnova Investments, Forbion, Dawn Biopharma, Venrock, Sanofi Ventures, Logos Capital, Biotechnology Value Fund, Balyasny, Adage | ||||